Baxter International Inc. · NYSE:BAX
Baxter International — Raymond James 41st Annual Institutional Investors Conference (March 2020)
16 slides from Baxter International's conference presentation, Mar 2, 2020
Slide 1: Raymond James 41st Annual Institutional Investors Conference
Raymond James 41st Annual Institutional Investors Conference Jay Saccaro, EVP & Chief Financial Officer March 2, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning the company’s preliminary operating results, preliminary sales and operating margin outlook for the year 2020, business development activities, growth drivers, portfolio innovation, market development and strategi
Slide 3: Uniquely Positioned To Deliver Value To Stakeholders
Uniquely Positioned To Deliver Value To Stakeholders Baxter Key Competencies Medically necessary Reach and experience Global manufacturing products and therapies across all sites of care expertise For Over 85 Years, Baxter Has Operated At The Critical Intersection Of Saving And Sustaining Lives 3
Slide 4: A Global & Diversified Portfolio
A Global & Diversified Portfolio Preliminary Full-Year 2019 Results1,2 $11.4B Global Revenue Renal Care Medication Delivery Pharmaceuticals $3.6B | +3% $2.8B | +7% $2.2B | +6% +5% Constant Currency Revenue Growth Market Leadership Clinical Nutrition Advanced Surgery Acute Therapies Across Portfolio
Slide 5: Top Quartile Goals / Our Strategy
Top Quartile Goals Patient safety and Quality Best place to work Growth through innovation Industry leading performance Our Strategy Strengthen our portfolio and extend our impact through transformative innovation that spans prevention to recovery 5
Slide 6: Prioritizing Patient Safety And Quality
Prioritizing Patient Safety And Quality Investing in quality systems and processes Improving key quality metrics through targeted initiatives Strengthening relationships with global regulators Closed five legacy FDA warning letters since 2015 6
Slide 7: Making A Meaningful Difference
Making A Meaningful Difference A Recognized Top Employer And Outstanding Corporate Citizen Serving Our Recent Highlights Communities Worldwide Reducing Our Environmental Footprint Expanding Access To Care Focusing On Inclusion and For more information on Baxter’s efforts to benefit our communities,
Slide 8: Strategic Growth Drivers
Strategic Growth Drivers Portfolio Market Strategic Innovation Development Partnerships Executing on pipeline Driving growth through evidence Expanding beyond the core to opportunities and geographic generation, physician education, unlock new therapies and expansion and market investments markets 8
Slide 9: Innovation Meeting The Needs Of Patients and Providers
Innovation Meeting The Needs Of Patients and Providers Recent Highlights Portfolio Market Strategic Innovation Development Partnerships Myxredlin PD Access In Q-NRG+ COSMED Ready-To-Use Support Of AAKHI3 Partnership PrisMax for VIBe4 Scale For CKD&Me Pilot With CRRT1 Bleed Severity Ayogo Spectrum IQ
Slide 10: Robust Pipeline Fueling Future Growth
Robust Pipeline Fueling Future Growth1 2020+ Highlights Expanded Pump Offerings Planned launches of Large Volume, Syringe, Patient Controlled Analgesia, and Ambulatory pumps Sharesource Analytics Enhanced data analytics to support improved patient care and shared decision-making PIVA Specialized Mon
Slide 11: Furthering Our Potential Through Business Transformation
Furthering Our Potential Through Business Transformation Realized $1.0B+ Savings Pursuing Further Opportunities To Date Vs. 2015 For Operational Efficiency ~$1.2B Strategic Growth ~$1.1B Allocating resources to support effective ~$1.0B R&D and commercial execution Operations Optimization Simplifying
Slide 12: Unlocking Additional Value Through Strategic Capital Deployment
Unlocking Additional Value Through Strategic Capital Deployment Reinvestment In Business Investing in meaningful innovation and growth acceleration opportunities, including various Renal Care initiatives such as AAKHI support Dividend Issuance Increased quarterly dividend payment by 16% to $0.22 per
Slide 13: Disciplined Execution Of Our M&A Strategy
Disciplined Execution Of Our M&A Strategy Objectives & Criteria: Recent Announcements Drive Category Cheetah Medical Leadership • Accelerates Baxter’s entry into specialized monitoring and supports efforts to personalize therapy and help eliminate preventable harm Capitalize On • Upfront cash paymen
Slide 14: Full-Year 2020 Preliminary Financial Guidance
Full-Year 2020 Preliminary Financial Guidance1,2 Full-Year 2020 Preliminary Guidance Sales Growth 4% - 5% Reported Foreign Exchange ~0 bps Sales Growth 4% - 5% Constant Currency GAAP Operating Margin 17% - 18% Adjusted Operating 19% - 20% Margin 1Non-GAAP financial metrics referenced on this slide i
Slide 15: Continuing Momentum In 2020 And Beyond
Continuing Momentum In 2020 And Beyond • Executing on new product launches, market development, and geographic expansions • Strategically investing in quality and operations to support expansion opportunities • Integrating recent tuck-in acquisitions to unlock additional value • Realizing ongoing be
Slide 16: Raymond James 41st Annual Institutional Investors Conference
Raymond James 41st Annual Institutional Investors Conference Jay Saccaro, EVP & Chief Financial Officer March 2, 2020